Kurathong P, Jesdapatarakul S
Department of Medicine, Bangkok Metropolitan Administration Medical College, Thailand.
J Med Assoc Thai. 2000 Mar;83(3):315-24.
Even though it is the most common primary glomerular disease, the natural history and prognosis of IgM associated nephrotic syndrome have not been well established.
To determine the (1) responsiveness to prednisolone therapy, (2) long-term clinical and laboratory outcomes, and (3) prognostic indicators to prednisolone therapy in patients with IgM associated nephrotic syndrome.
Clinical descriptive, longitudinal study.
Seventy two biopsy-proved IgM associated nephrotic syndrome patients, diagnosed between 1978-1996 at Vajira Hospital, Bangkok, were included in the study.
Clinical parameters with age, sex, duration of edema, blood pressure and laboratory findings such as hematuria, BUN, creatinine, albumin, and cholesterol, 24-hour urine protein, and stool examination, were collected pre-renal biopsy. Each patient was treated with 45-60 mg of prednisolone according to body weight, for up to 8 weeks. Each patient was followed-up every 4-weeks for clinical and laboratory evaluations, and for adjusting the steroid dosage. Clinical responses were stratified into 3 groups as steroid responsive (SRP), steroid dependent (SD), and steroid resistant (SRS).
(1) Frequency and types of steroid responsiveness. (2) Incidence of hypertension, hematuria, renal insufficiency, end-stage renal disease, and survival during the follow-up. (3) Prognostic indicators for initial clinical response to prednisolone, and for long-term morbidity and mortality.
Forty eight of the 72 patients (66.67%) were responsive to prednisolone at 8-weeks, the 24 remaining patients (33.33%) were nonresponsive. High proteinuria of 7.66 +/- 4.14 g/D was the only good prognostic indicator to initial prednisolone therapy (p < 0.03). During the follow-up, 42(58.33%), 26(36.11%), and 4(5.56%) patients were SRP, SD, and SRS, respectively. There were no prognostic indicators associated with long-term steroid responsiveness. Of the 60 patients followed-up for more than one year; 34, 15 and 11 patients were followed-up for 1-5, > 5-10 and > 10 years, respectively. Hematuria and proteinuria were more frequent among the SRS group (p < 0.01 and 0.02, respectively) during the follow-up. Only one patient, initially in the SD group, and later on became SRS, died.
Patients with IgM associated nephrotic syndrome had very good response to prednisolone therapy. It had a very slow progressive course, with low morbidity and mortality.
尽管IgM相关性肾病综合征是最常见的原发性肾小球疾病,但其自然病程和预后尚未完全明确。
确定(1)IgM相关性肾病综合征患者对泼尼松龙治疗的反应性;(2)长期临床和实验室结果;(3)泼尼松龙治疗的预后指标。
临床描述性纵向研究。
纳入72例经活检证实的IgM相关性肾病综合征患者,于1978年至1996年在曼谷瓦吉拉医院确诊。
在肾活检前收集临床参数,包括年龄、性别、水肿持续时间、血压以及血尿、血尿素氮、肌酐、白蛋白、胆固醇、24小时尿蛋白和粪便检查等实验室检查结果。根据体重,每位患者接受45 - 60mg泼尼松龙治疗,疗程长达8周。每4周对每位患者进行随访,进行临床和实验室评估,并调整类固醇剂量。临床反应分为3组:类固醇反应型(SRP)、类固醇依赖型(SD)和类固醇抵抗型(SRS)。
(1)类固醇反应性的频率和类型;(2)随访期间高血压、血尿、肾功能不全、终末期肾病的发生率及生存率;(3)泼尼松龙初始临床反应以及长期发病率和死亡率的预后指标。
72例患者中有48例(66.67%)在8周时对泼尼松龙有反应,其余24例(33.33%)无反应。初始泼尼松龙治疗时,蛋白尿>7.66±4.14g/天是唯一良好的预后指标(p<0.03)。随访期间,分别有42例(58.33%)、26例(36.11%)和4例(5.56%)患者为SRP、SD和SRS。没有与长期类固醇反应性相关的预后指标。60例随访超过1年的患者中,分别有34例、15例和11例患者随访了1 - 5年、>5 - 10年和>10年。随访期间,SRS组血尿和蛋白尿更为常见(分别为p<0.01和0.02)。仅1例患者死亡,该患者最初为SD组,后来转变为SRS组。
IgM相关性肾病综合征患者对泼尼松龙治疗反应良好。其病程进展非常缓慢,发病率和死亡率较低。